Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01515969
Recruitment Status : Terminated (Patient safety - Unacceptable toxicity)
First Posted : January 24, 2012
Last Update Posted : July 12, 2016
Genentech, Inc.
Information provided by (Responsible Party):
Heather Wakelee, Stanford University

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : February 2013
  Actual Study Completion Date : December 2014